The Impact of Hepcidin in Diabetic Patients with Nephropathy
(A new reading in the comparison between the creations of Meyerhold and Brecht)
Keywords:
Hepcidin, Diabetic nephropathy, chronic kidney disease (CKD)Abstract
Chronic kidney disease (CKD) is one of the complications of diabetes. It is a dangerous disease the high mortality rate.This disease is accompanied with anemia, which is due to an imbalance in the secretion of the hormone erythropoietin. There is no biological factor evaluating the two cases linked to indicate the state of the disease. Hence the need for a vital indicator that helps assesses the deterioration of the disease. A total of 45 diabetic patients with nephropathy complication in different stage from out-patient clinic of the National Centre for Diabetes Treatment and Research, Mustansiriyah University were enrolled in the study. The patients were divided to three groups: (Group A) fifteen patients; normalalbumin-uria (albumin excretion in urine persistently lower than 30 mg/d), fifteen patients with microalbuminuria (albumin 30-300 mg/d), and macro-albuminuria (albumin ˃ 300 mg/d). Serum hepcidin, Fasting plasma glucose, hemoglobin, blood urea and creatinine were measured. There are a significant difference in serum hepcidin levels in control group (66.34±12.4 ng/ml) when compared to diabetic patients (92.41±27.33ng/m). Serum hepcidin also elevated in macro-albumin urea group (195.32±31.16 ng/ml) when compare to other groups. Hepcidin levels elevated in diabetic patients and more increase in macro and micro-albumin urea.
Downloads
References
Gafter-Gvili A. Schechter A. Rozen-Zvi
B. Iron Deficiency Anemia in Chronic
Kidney Disease. Acta Haematol. 2019;
(1): 44-50. doi.org/10.1159/000496492
Atkinson MA. Warady BA. Anemia in
chronic kidney disease. Pediatr Nephrol.
; 33(2): 227-238.Doi.org/10.1007/s00467-017-3663-y.
Santos-Silva A. Ribeiro S. Reis F. Belo L.
Hepcidin in chronic kidney disease
anemia. Vitam Horm. 2019; 110: 243-264.
doi.org/10.1016/bs.vh.2019.01.012.
Ueda N. Takasawa K. Impact of
Inflammation on Ferritin, Hepcidin and
the Management of Iron Deficiency
Anemia in Chronic Kidney Disease.
Nutrients. 2018; 10(9): 1173.
doi.org/10.3390/nu10091173.
Chen N. Hao C. Peng X. Lin H. Yin A.
Hao L. Tao Y. Liang X. Liu Z. Xing C. et
al. Roxadustat for Anemia in Patients with
Kidney Disease Not Receiving Dialysis. N
Engl J Med. 2019; 381(11): 1001-
doi.org/10.1056/NEJMoa1813599.
Leung D. Berg J. Witcher DR. Targeting
the hepcidin-ferroportin pathway in
anaemia of chronic kidney disease. Br J
Clin Pharmacol. 2019; 85(5): 935-948.
doi.org/10.1111/bcp.13877.
Sonkar SK. Singh NK. Sonkar GK.
Pandey S. Bhosale V. Kumar A. Usman
K. Association of hepcidin and anemia in
early chronic kidney disease. Saudi J
Kidney Dis Transpl. 2019; 30(2): 315-324.
DOI: 10.4103/1319-2442.256838.
Nakanishi T. Kimura T. Kuragano T. The
Hepcidin-Anemia Axis: Pathogenesis of
Anemia in Chronic Kidney Disease.
Contrib Nephrol. 2019; 198: 124-134.
doi.org/10.1159/000496636
Artin ER. Smith MT. Maroni BJ. Zuraw
QC. deGoma EM. Clinical Trial of
Vadadustat in Patients with Anemia
Secondary to Stage 3 or 4 Chronic Kidney
Disease. Am J Nephrol. 2017; 45(5): 380-
doi.org/10.1159/000464476.
Hilde PE Peters. Coby MM
Laarakkers. Dorine W Swinkels. Jack FM
Wetzels. Serum hepcidin-25 levels in
patients with chronic kidney disease are
independent of glomerular filtration rate.
Nephrol Dial Transpl. 2010; 25(3): 848-
doi.org/10.1093/ndt/gfp546.
Agarwal AK. Yee J. Hepcidin. Adv
Chronic Kidney Dis. 2019; 26(4): 298-
DOI: 10.1053/j.ackd.2019.04.005.
Lergola PE. Spinowitz BS. Hartman CS.
Maroni BJ. Haase VH. Vadadustat, a
novel oral HIF stabilizer, provides
effective anemia treatment in nondialysisdependent chronic kidney disease. Kidney
Int. 2016; 90(5): 1115-22.
doi.org/10.1016/j.kint.2016.07.019.
Min HK. Sung SA. Oh YK. Kim YH.
Chung W. Park SK. Ahn C. Lee SW.
Hepcidin, iron indices and bone mineral
metabolism in non-dialysis chronic kidney
disease. Nephrol Dial Transplant. 2020;
(1): 147-54.
doi.org/10.1093/ndt/gfy235
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
